Literature DB >> 8157354

Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors.

M J Bello1, J Vaquero, J M de Campos, M E Kusak, J L Sarasa, J Saez-Castresana, A Pestana, J A Rey.   

Abstract

Alterations of the short arm of chromosome 1 are recurrently found in cytogenetic analysis of malignant gliomas, and deletions of 1p36-p32 region characterize at least the higher-grade tumors, glioblastoma multiforme. Molecular analysis of tumor-derived and normal genomic DNA from 57 cases of gliomas, using a panel of chromosome 1-specific DNA probes showed LOH in 16 tumors. Allelic losses on 1p were primarily restricted to glioblastoma multiforme (2/11) and to tumors with a major oligodendroglial component: grade II oligodendrogliomas (6/6), grade III anaplastic oligodendrogliomas (5/6) and grade II-III mixed oligo-astrocytomas (2/3). Losses for 1q markers were detected in only 1 tumor (glioblastoma multiforme). Our data suggest that anomalies of 1p primarily characterize oligodendrogliomas, whereas they are rare events in astrocytic tumors and indicate that a tumor-suppressor gene on 1p36-p32 is involved in the development of brain tumors with oligodendroglial differentiation.

Entities:  

Mesh:

Year:  1994        PMID: 8157354     DOI: 10.1002/ijc.2910570207

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma.

Authors:  S Ozaki; T Nishizaki; H Ito; K Sasaki
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 3.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

Authors:  J Mora; N K Cheung; B H Kushner; M P LaQuaglia; K Kramer; M Fazzari; G Heller; L Chen; W L Gerald
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

4.  Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.

Authors:  M Gibbs; J L Stanford; R A McIndoe; G P Jarvik; S Kolb; E L Goode; L Chakrabarti; E F Schuster; V A Buckley; E L Miller; S Brandzel; S Li; L Hood; E A Ostrander
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Yoshinori Higuchi; Naokatsu Saeki
Journal:  J Neurooncol       Date:  2010-08-19       Impact factor: 4.130

Review 6.  Malignant glioma: neuropathology and neurobiology.

Authors:  Matthias Preusser; Christine Haberler; Johannes A Hainfellner
Journal:  Wien Med Wochenschr       Date:  2006-06

7.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

Review 8.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

9.  Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.

Authors:  Brian Thiessen; John A Maguire; Kelly McNeil; David Huntsman; Montgomery A Martin; Doug Horsman
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

10.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

Authors:  Fabio M Iwamoto; Linda Nicolardi; Alexis Demopoulos; Violetta Barbashina; Paulo Salazar; Marc Rosenblum; Adília Hormigo
Journal:  J Neurooncol       Date:  2008-03-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.